Open Orphan, the European-focused rare and orphan drug consulting services business, has signed five pharmaceutical and biotechnology companies as early adopters of its Genomic Health databank platform.
Rare Disease Database
The platform is due to be completed next year and is set to establish a rare disease database. The five companies who have signed up to it aim to ensure that its fit for purpose from a pharmaceutical and data analysis perspective ahead of the first patient data upload.
Please register or login to comment!
Register now Login